Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

  • STATUS
    Not Recruiting
  • End date
    Nov 14, 2022
  • participants needed
    40
  • sponsor
    CSL Behring
Updated on 8 August 2022
antibiotic therapy
antibiotics
absolute neutrophil count
psoriasis
systemic therapy
hidradenitis
monoclonal antibody
g-csf
phototherapy
topical agents
hidradenitis suppurativa
palmoplantar pustulosis

Summary

Study CSL324_1002 will investigate the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis. CSL324 is a novel, recombinant therapy that may treat diseases caused by increased numbers of neutrophils at sites of inflammation.

Details
Condition Hidradenitis Suppurativa, Palmoplantar Pustulosis
Treatment Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
Clinical Study IdentifierNCT03972280
SponsorCSL Behring
Last Modified on8 August 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note